As the sponsor, you must report unexpected fatal or life‑threatening suspected adverse reactions to FDA within 7 calendar days of initial receipt, and other serious, unexpected reactions within 15 calendar days of your determination, under 21 CFR 312.32. Since April 1, 2026, serious and unexpected suspected adverse reactions go to AEMS in E2B(R3) format. Findings from other studies, animal or in vitro testing, and increased event rates are submitted in eCTD. Noncommercial INDs are exempt from the AEMS requirement.
TL;DR:
- Log each site report with its receipt time, reporter, participant identifier, and event details; preserve a traceable audit trail and record who made each determination.
- For other serious, unexpected reactions, record the determination’s timestamp because it starts the reporting clock; prompt triage prevents site delays from consuming available time.
- Other reportable findings include signals in studies, literature, or animal and laboratory tests, plus clinically important increases in serious reaction rates.
- FDA recommends a safety committee and surveillance plan covering thresholds, review cadence, unblinding rules, and records; convene extra reviews when serious unexpected events arrive.
- Train investigators to report suspected drug related events promptly, capture onset and awareness dates, and define which cases require a phone call.
Table of Contents
- How does the sponsor workflow run from intake to submission?
- What triggers a 7 day versus a 15 day report?
- Which submission channel applies to each report?
- How should you set up a safety assessment committee and surveillance plan?
- What do investigators owe sponsors, and how do you capture it?
- How do you handle follow-up reports and inspection records?
- How does FDA screen your submission on arrival?
- Where do sponsors usually fail, and what fixes it?
- How do we help you build a safety reporting workflow that holds up?
- FAQ
- Sources
How does the sponsor workflow run from intake to submission?
A defensible workflow is a sequence of timestamped handoffs. Each step below should leave a record an inspector can follow.
- Log every site report on arrival. Record the time of receipt, the reporter, the participant identifier and the event description in an intake log that cannot be edited without a trace.
- Triage at once. Decide whether the event is serious and whether it is unexpected against the protocol and the Investigator's Brochure.
- Escalate ambiguous cases. Send unclear events or possible aggregate signals to your safety assessment committee.
- Document your determination. Write down who decided, on what evidence and when, because that timestamp starts the 15 day clock for non-fatal events.
- Draft the IND safety report. Reference similar prior reports and analyze what the new event adds to the picture.
- Notify and submit. Notify FDA and participating investigators inside the applicable window, then archive the submission confirmation with the intake record.
Pro Tip: Set an internal service level for triage so the gap between site receipt and your determination does not consume the regulatory window.
What triggers a 7 day versus a 15 day report?
FDA's IND safety reporting page sets the two clocks. A suspected adverse reaction that is serious, unexpected and fatal or life‑threatening starts a 7 day clock at initial receipt. Other serious and unexpected suspected adverse reactions, plus certain other findings, must be reported within 15 calendar days after your determination.
The qualifying triggers are:
- A serious and unexpected suspected adverse reaction that is not fatal or life‑threatening.
- Findings from other studies, epidemiological data or published literature that suggest a significant risk to participants.
- Findings from animal or in vitro testing that suggest a significant risk, such as hERG assay results pointing to cardiac liability.
- A clinically important increase in the rate of a serious suspected adverse reaction over what the protocol or brochure anticipates.
Fatal or life‑threatening, unexpected suspected reactions: 7 calendar days from initial receipt.
Because your determination anchors the 15 day clock, the audit trail matters as much as the decision. Our guidance on FDA audit trail requirements covers timestamping practices that hold up in inspection.
Which submission channel applies to each report?
As of April 1, 2026, serious and unexpected suspected adverse reactions under 21 CFR 312.32(c)(1)(i) must be submitted electronically to the FDA Adverse Event Monitoring System (AEMS) using E2B(R3) data standards, either by database-to-database transmission or through the Safety Reporting Portal. Plan your safety database configuration and portal access well before your first reportable event, not after it.
- Findings from other studies, animal or in vitro testing, and increased event rates are submitted in eCTD format.
- Check FDA's reporting page for the submission requirements that apply to your IND.
- You may request a submission tracking number (STN) as part of the electronic process, and FDA's SOPP 8217 describes how commercial IND submissions are handled administratively.
How should you set up a safety assessment committee and surveillance plan?
FDA's Safety Assessment for IND Safety Reporting guidance recommends a safety assessment committee and a safety surveillance plan so that reportability decisions are systematic and documented. Staff the committee with the clinical specialties relevant to your population and a clinical pharmacology voice, and state in writing who may recommend that an event is reportable.
Your surveillance plan should cover:
- The list of anticipated events for the program.
- The thresholds that make an event or an aggregate trend reportable.
- How often the committee reviews data.
- The rules for unblinding when a blinded event needs analysis.
- The documentation each decision must produce.
Hold routine aggregate reviews on a fixed cadence, and convene ad hoc sessions the moment an unexpected serious event arrives. Minutes should capture the recommendation, the evidence and the time it was made.
Pro Tip: Build one committee template with fields for event, decision, rationale and clock start time, so every determination is recorded the same way.
What do investigators owe sponsors, and how do you capture it?
FDA's final guidance on investigator responsibilities for safety reporting, announced in December 2025, tells investigators to report adverse events reasonably regarded as caused by the investigational drug, and to report alarming events immediately. Their speed is what lets you meet your own deadlines. Industry commentary on the guidance in Clinical Leader stresses clearer investigator-to-sponsor reporting for the same reason.
- Design site intake forms with the required fields and a mandatory event onset and awareness date.
- Define escalation criteria that tell sites which events need a phone call, not an email.
- Train sites on what counts as reportable, and track site timeliness as a metric. Our risk-based monitoring setup shows how to monitor it.
How do you handle follow-up reports and inspection records?
You must promptly investigate safety information and submit follow-up IND safety reports as soon as more information becomes available. If an investigation shows that an event now meets the reporting criteria, you submit within 15 calendar days of that determination.
- Label each follow-up clearly and link it to the initial report.
- Keep cross-referenced files that show timelines, committee minutes and the data behind each determination.
- Preserve a record of each notification to participating investigators.
Dashboards help here. See how clinical trial dashboards can surface open reports and approaching deadlines.
How does FDA screen your submission on arrival?
According to MAPP 6030.9, CDER review staff prioritize submissions by subject safety and by their importance to the development program. A clearly organized submission with regulatory context speeds triage.
Label the submission "IND Safety Report," point to prior similar reports, and state any regulatory question up front. Include concise key data and background instead of burying reviewers in raw material, since incomplete or confusing packages add friction.
Where do sponsors usually fail, and what fixes it?
In our experience, the weakest link is rarely the regulation. It is the lag between a site learning of an event and your team making a determination. An intake log with a defined service level can help address that gap. Governance finishes the job: a fixed committee cadence, standard templates and governed automation keep determinations audit-ready. Clear escalation, site training and timeliness metrics are small changes that prevent missed deadlines.
— John
How do we help you build a safety reporting workflow that holds up?
We start with the clock, not the software. Our AI Velocity Diagnostic and operating partnership map where your safety reporting stalls, then we redesign the workflow around it.
- Safety-process redesign from site intake to FDA submission.
- Governance support for your safety assessment committee and surveillance plan.
- Governed automation that cuts internal lag between receipt and determination.
Review our clinical, scientific and regulatory operations work or request a diagnostic to test your IND safety reporting readiness.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
What are the FDA SUSAR reporting requirements?
Sponsors must report unexpected fatal or life‑threatening suspected adverse reactions within 7 calendar days of initial receipt. Other serious and unexpected suspected adverse reactions are due within 15 calendar days of the sponsor's determination, per FDA.
Is MedWatch reporting mandatory for IND safety reports?
IND safety reports follow 21 CFR 312.32 and, for serious and unexpected suspected adverse reactions, now go to AEMS in E2B(R3) format. Check FDA's reporting page for the channel that fits your report type.
What is required for an IND submission safety program?
You need a process to review safety information from all sources, determine reportability and submit reports on time. FDA also recommends a safety assessment committee and a surveillance plan, as described in its guidance.
What are the requirements for safety reporting in clinical trials?
Investigators report to sponsors promptly, and sponsors notify FDA and participating investigators within the applicable window. Each report should reference similar prior reports and analyze their significance.
Sources
- IND Application Reporting: IND Safety Reports | FDA
- Safety Assessment for IND Safety Reporting Guidance for Industry